Mirvaso (brimonidine)
- Region
- 🇪🇺 EU
- Active substance
- brimonidine
- Company
- Galderma S.A. (Netherlands Branch)
- Status
- Authorised
- Therapeutic area
- Skin Diseases
- EU approval
- Thu 20 Feb 2014
- Application
- EMEA/H/C/002642
- ATC
- D11AX21
- Official record
- www.ema.europa.eu
Indication
Mirvaso is indicated for the symptomatic treatment of facial erythema of rosacea in adult patients.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇺🇸 Yuvezzi Approved · Visus
- 🇪🇺 Simbrinza Authorised · Novartis Europharm Limited
Follow Mirvaso
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.